In vivo studies reveal that immunoliposomes conjugated with different ligands to target specific tumor antigens, for example, VCAM-1 [16], interleukin-13 [17], and EGFR [18], may be of important clinical significance as a novel treatment for cancer. This evidence concerns the gene VCAM1 and cancer.